Acute myeloid leukemia (AML) is a complex hematopoietic clonal disorder with limited curative options beyond stem cell transplantation. The success of transplant is intimately linked with the graft versus leukemia effect from the alloreactive donor immune cells including, T and NK cells. The immune system plays a dynamic role in leukemia survival and resistance. Despite our growing understanding of the immune microenvironment, responses to immune-based therapies differ greatly between patients. Herein, we review the biology of immune evasion mechanisms in AML, discuss the current landscape of immunotherapeutic strategies, and discuss the implications of therapeutic targets. This review focuses on T and NK cell-based therapy, including modified and non-modified NK cells, CAR-T and CAR-NK cells, antibodies, and checkpoint blockades. Understanding the complex interchange between immune tolerance and the emergence of tumor resistance will improve patient outcomes.
急性髓系白血病（AML）是一种复杂的造血克隆性疾病，除干细胞移植外治疗手段有限。移植的成功与异体反应性供体免疫细胞（包括T细胞和NK细胞）产生的移植物抗白血病效应密切相关。免疫系统在白血病存活和耐药过程中发挥着动态调节作用。尽管我们对免疫微环境的认识不断深入，但患者对免疫疗法的反应存在显著差异。本文系统综述了AML的免疫逃逸机制生物学，探讨了当前免疫治疗策略的发展现状，并分析了治疗靶点的临床意义。本综述重点关注基于T细胞和NK细胞的治疗策略，包括修饰与非修饰NK细胞、CAR-T与CAR-NK细胞、抗体疗法及免疫检查点阻断疗法。深入理解免疫耐受与肿瘤耐药产生之间的复杂相互作用机制，将有助于改善患者临床预后。
The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies
肿瘤(癌症)患者之家